BUY MBP PEGYLATED LIPOSOMAL DOXORUBICIN PEG-ADRIM 50MG VIAL BEST PRICE ONLINE IN NIGERIA LAGOS ABUJA KANO AND PORTHARCOURT AT MYBIGPHARMACY.COM

Description

Dear friend, this medication requires a prescription or medical license before it can be delivered to you. kindly ensure that you provide us with a reliable contact information at checkout, mybigpharmacy team will be in touch with you to obtain required document before your order is confirmed thank you for trusting mybig pharmacy with your health. Pegylated liposomal doxorubicin is a chemotherapy medicine used to treat several types of cancer, including ovarian cancer, breast cancer, multiple myeloma, Kaposi?s sarcoma, and some other solid tumours. It is a modified form of the chemotherapy drug doxorubicin, designed to improve effectiveness while reducing some of the serious side effects associated with standard doxorubicin.

Pegylated liposomal doxorubicin works by damaging the DNA inside cancer cells, which stops them from growing and dividing. Cancer cells divide much faster than normal cells, so they are more affected by this damage. What makes this medicine different is that the doxorubicin is enclosed inside tiny fat-like particles called liposomes and coated with a substance called polyethylene glycol, or PEG. This special coating allows the drug to stay in the bloodstream longer and concentrate more in tumour tissue while reducing exposure to healthy tissues such as the heart.

Because of this design, pegylated liposomal doxorubicin tends to cause fewer heart-related side effects compared to standard doxorubicin, although careful monitoring is still required. It is usually given as an intravenous infusion in a hospital or oncology clinic, often every 3 to 4 weeks, depending on the type of cancer being treated and how the body responds.

During treatment, patients may experience side effects such as fatigue, nausea, vomiting, loss of appetite, mouth sores, and changes in taste. A common side effect specific to this medicine is a skin reaction known as hand-foot syndrome. This can cause redness, swelling, pain, tingling, or peeling of the skin on the palms of the hands and soles of the feet. Keeping the skin moisturised, avoiding heat or friction, and reporting early symptoms can help reduce severity.

Hair thinning or hair loss may occur, but it is often less severe compared to conventional doxorubicin. Some patients may also experience mild swelling, skin darkening, or sensitivity to sunlight.

Pegylated liposomal doxorubicin can affect blood cell counts, leading to low white blood cells, red blood cells, or platelets. This may increase the risk of infections, fatigue, or bleeding. Regular blood tests are required to monitor these levels, and treatment may be delayed or adjusted if counts are too low.

Although this formulation reduces heart toxicity compared to standard doxorubicin, there is still a risk of heart damage, especially with high cumulative doses or in people with existing heart disease. Doctors may perform heart function tests such as echocardiograms before and during treatment.

Infusion-related reactions may occur, especially during the first dose. These can include flushing, shortness of breath, chest tightness, or back pain. For this reason, the drug is given slowly and patients are closely monitored during the infusion. If reactions occur, the infusion can be slowed or stopped and supportive treatment given.

Pegylated liposomal doxorubicin can harm an unborn baby and should not be used during pregnancy. Effective contraception is required during treatment and for some time afterward. Breastfeeding is not recommended during treatment.

Patients receiving this medicine should report symptoms such as fever, signs of infection, chest pain, shortness of breath, severe fatigue, mouth ulcers, or skin changes promptly. Good hydration, gentle skin care, and regular follow-up appointments are important during treatment.

When used appropriately under specialist supervision, pegylated liposomal doxorubicin is an effective chemotherapy option that offers targeted cancer treatment with improved tolerability compared to traditional formulations.